share_log

We Think Yifeng Pharmacy Chain (SHSE:603939) Can Stay On Top Of Its Debt

We Think Yifeng Pharmacy Chain (SHSE:603939) Can Stay On Top Of Its Debt

我們認爲益豐藥房(滬市:603939)能夠控制債務。
Simply Wall St ·  06/28 19:24

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We note that Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) does have debt on its balance sheet. But the more important question is: how much risk is that debt creating?

伯克希爾哈撒韋的穆尼爾(Munger)支持的外部基金經理人李錄(Li Lu)毫不掩飾地說:“最大的投資風險不是價格波動,而是你是否會遭受永久性資本損失。”因此,當您考慮任何給定股票的風險時,您需要考慮債務,因爲過多的債務可能會拖垮一家公司。我們注意到,益豐藥房股份有限公司(SHSE:603939)的資產負債表上確實有債務。但更重要的問題是:這些債務產生了多少風險?

What Risk Does Debt Bring?

債務帶來了什麼風險?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. The first step when considering a company's debt levels is to consider its cash and debt together.

一般來說,只有當公司無法輕鬆償還債務時,債務才會成爲真正的問題,無論是通過籌資還是通過自己的現金流。資本主義的一個方面是“創造性破壞”過程,失敗的企業會被銀行家殘忍地清算。儘管這並不常見,但我們經常看到負債公司因貸款人強迫其以窘迫的價格籌集資本而永久稀釋股東。當然,債務的好處在於它經常代表廉價資本,尤其是當它代替了公司具有以高回報率再投資能力的稀釋時。在考慮公司債務水平時的第一步是考慮其現金和債務總額。

What Is Yifeng Pharmacy Chain's Debt?

益豐藥房的債務情況如何?

The image below, which you can click on for greater detail, shows that at March 2024 Yifeng Pharmacy Chain had debt of CN¥3.22b, up from CN¥1.60b in one year. But on the other hand it also has CN¥6.98b in cash, leading to a CN¥3.76b net cash position.

下面的圖像(單擊可放大)顯示,到2024年3月,益豐藥房的債務爲32.2億人民幣,比一年前的16億人民幣增加了一倍。不過,它也有69.8億人民幣的現金,形成了37.6億人民幣的淨現金頭寸。

debt-equity-history-analysis
SHSE:603939 Debt to Equity History June 28th 2024
SHSE:603939股權和負債歷史圖表,截至2024年6月28日

A Look At Yifeng Pharmacy Chain's Liabilities

查看益豐藥房的負債情況

We can see from the most recent balance sheet that Yifeng Pharmacy Chain had liabilities of CN¥11.1b falling due within a year, and liabilities of CN¥4.01b due beyond that. On the other hand, it had cash of CN¥6.98b and CN¥2.86b worth of receivables due within a year. So it has liabilities totalling CN¥5.26b more than its cash and near-term receivables, combined.

我們可以從最近的資產負債表中看到,益豐藥房在一年內到期的負債爲111億元人民幣,超過一年到期的負債爲40.1億元人民幣。另一方面,它有69.8億人民幣的現金和28.6億元人民幣的應收賬款。因此,它的負債總額比其現金和短期應收款項還要多。

Of course, Yifeng Pharmacy Chain has a market capitalization of CN¥29.8b, so these liabilities are probably manageable. Having said that, it's clear that we should continue to monitor its balance sheet, lest it change for the worse. Despite its noteworthy liabilities, Yifeng Pharmacy Chain boasts net cash, so it's fair to say it does not have a heavy debt load!

當然,益豐藥房的市值爲298億元人民幣,所以這些負債可能是可管理的。儘管如此,很明顯我們應繼續監測它的資產負債表,以免惡化。儘管它的負債有目共睹,但益豐藥房擁有淨現金,因此公平地說,它的債務負擔並不沉重!

The good news is that Yifeng Pharmacy Chain has increased its EBIT by 4.6% over twelve months, which should ease any concerns about debt repayment. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if Yifeng Pharmacy Chain can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

好消息是,益豐藥房在過去的12個月中EBIT增長了4.6%,這應該能緩解關於償還債務的擔憂。毫無疑問,我們從資產負債表中學到了大部分關於債務的信息。但最終業務的未來盈利能力將決定益豐藥房是否能隨着時間的推移加強其資產負債表。因此,如果您關注未來,可以查看這份免費報告,了解分析師的盈利預測。

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. Yifeng Pharmacy Chain may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Over the last three years, Yifeng Pharmacy Chain actually produced more free cash flow than EBIT. There's nothing better than incoming cash when it comes to staying in your lenders' good graces.

但我們最後考慮的也很重要,因爲公司無法以紙面利潤支付債務;它需要現金。益豐藥房可能會在資產負債表上擁有淨現金,但是還是有必要看看企業將其利息和稅前利潤(EBIT)轉化爲自由現金流的能力如何,因爲這將影響其管理債務的需求和能力。在過去的三年中,益豐藥房的自由現金流比EBIT還多。在這方面,進賬的現金比任何債權人都有用。

Summing Up

總之

While Yifeng Pharmacy Chain does have more liabilities than liquid assets, it also has net cash of CN¥3.76b. The cherry on top was that in converted 155% of that EBIT to free cash flow, bringing in CN¥3.2b. So we don't think Yifeng Pharmacy Chain's use of debt is risky. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. These risks can be hard to spot. Every company has them, and we've spotted 1 warning sign for Yifeng Pharmacy Chain you should know about.

儘管益豐藥房的負債多於流動資產,但它也有37.6億元人民幣的淨現金。此外,它還將其EBIT的155%轉化爲自由現金流,獲取了32億元人民幣的現金。因此,我們認爲益豐藥房使用債務並不冒險。在分析債務水平時,資產負債表是顯而易見的起點。但是,並不是所有的投資風險都來自資產負債表-遠非如此。這些風險可能很難發現。每個公司都有它們,我們已經發現益豐藥房有1個警示標誌,您應該了解一下。

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

如果您有興趣投資能夠在不負債的情況下增長利潤的企業,請查看這份免費列表,其中列出了在資產負債表上擁有淨現金的成長型企業。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論